S100A10 and hepatocellular carcinoma: Up to now, S100A10 has been reported to be up-regulated in several cancers, including lung cancer [8], gall bladder adenocarcinoma [9], colorectal adenocarcinoma [10], and hepatocellular carcinoma [11], which correlated with worse survival outcomes.